Fulcrum Pharmaceuticals Appoints Charles N. Blitzer President and Chief Executive Officer.
"We are pleased to welcome Chuck Blitzer to Fulcrum and expand our management team with such a talented professional at this important time in our company's history," said Sam Milstein, Ph.D., founder, chairman and chief science officer of Fulcrum. "Chuck's extensive business development and overall leadership experience in the pharmaceutical and biotechnology industries provides him with an ideal background to run a development stage company such as Fulcrum. He will play a critical role in managing our growth and development."
Mr. Blitzer has more than 25 years of experience at senior level executive positions in large and small pharmaceutical companies, ranging from management to legal, strategic planning and business development. Most recently, Mr. Blitzer served as Chairman and CEO of publicly traded MGI Pharma (NASDAQ: MOGN), an oncology based company.
"I look forward to working with Fulcrum's strong scientific team as we advance the company's strategies and accelerate the process of commercializing Fulcrum's emerging pipeline of exciting compounds," said Chuck Blitzer, chief executive officer. "Fulcrum has a unique discovery technology platform developed by leading scientists, a strong patent portfolio, the backing of a phenomenal investor group, and a team with the commitment necessary to deliver new breakthrough products from our lead compound portfolio of protein mimetics and small molecule inhibitors."
Prior to joining MGI Pharma and then Fulcrum, Mr. Blitzer served as President and Chief Executive Officer at Oncologix, Inc., which merged with publicly held Argus Pharmaceuticals in September 1995. Prior to Oncologix, Mr. Blitzer worked for Marion Laboratories/Marion Merrell Dow from 1977 to 1992 in various capacities, including General and Patent Counsel and Vice President-Licensing & Business Development. Mr. Blitzer received a Bachelor of Science degree from the University of Toledo's School of Pharmacy, a Juris Doctor from American University's Washington College of Law and a Master of Business Administration degree from Rockhurst College in Kansas City, Missouri.
Fulcrum Pharmaceuticals applies computational chemistry, structural biology and thermodynamics to achieve accelerated design and development of drug products. Founded in 2002, Fulcrum has already amassed a portfolio of proprietary lead compounds targeted at inflammatory disease, osteoporosis, infectious disease and oncology. This portfolio includes small molecule inhibitors of receptors and enzymes, small molecule mimics of antibodies and receptors, and "adaptive" anti-infectives (drugs capable of overcoming resistance). Fulcrum's strategy is to out-license a portion of its pipeline, while retaining selected compounds for its own development. For more information, visit www.fulcrumpharmaceuticals.com.